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SUMMARY

RNA sequencing (RNA-seq) detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen
receptor-positive (ER+) breast cancer, but their role
in disease pathogenesis remains unclear. We examined multiple ESR1 fusions and found that two, both
identified in advanced endocrine treatment-resistant
disease, encoded stable and functional fusion
proteins. In both examples, ESR1-e6>YAP1 and
ESR1-e6>PCDH11X, ESR1 exons 1–6 were fused in
frame to C-terminal sequences from the partner
gene. Functional properties include estrogen-independent growth, constitutive expression of ER target
genes, and anti-estrogen resistance. Both fusions
activate a metastasis-associated transcriptional pro-

gram, induce cellular motility, and promote the
development of lung metastasis. ESR1-e6>YAP1and ESR1-e6>PCDH11X-induced growth remained
sensitive to a CDK4/6 inhibitor, and a patient-derived
xenograft (PDX) naturally expressing the ESR1e6>YAP1 fusion was also responsive. Transcriptionally active ESR1 fusions therefore trigger both endocrine therapy resistance and metastatic progression,
explaining the association with fatal disease progression, although CDK4/6 inhibitor treatment is predicted to be effective.
INTRODUCTION
The etiology of endocrine therapy resistance in estrogen receptor-positive (ER+) breast cancer is complex (Ma et al., 2015) but
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includes acquired somatic mutations within the ligand-binding
domain (LBD) of the estrogen receptor gene (ESR1) causing
ligand-independent activation (Pejerrey et al., 2018). RNA
sequencing (RNA-seq) has also identified multiple ESR1 gene
fusion events, but their role in endocrine therapy resistance
and how they might be targeted therapeutically is unclear
(Giltnane et al., 2017). The majority of ESR1 fusion transcripts
have been identified in primary breast cancer, and in some of
these instances patients have high-grade disease and/or resistance to endocrine therapy (Giltnane et al., 2017; Veeraraghavan
et al., 2014), implying some functionality. In some cases, up to
five ESR1 coding exons are included (exons 3–7), mostly fused
out of frame but occasionally, and more interestingly, in frame.
However, detailed characterization of the predicted chimeric
proteins and a clear demonstration of a causal role for ESR1
fusions in endocrine therapy resistance have been largely
lacking.
Several years ago, our group described an unequivocal stable
and functional ESR1 fusion protein (Li et al., 2013). This was an
in-frame fusion gene consisting of exons 1–6 of ESR1 fused to
C-terminal sequences from the Hippo pathway coactivator
YAP1 (ESR1-e6>YAP1), identified in a metastatic sample and
matched patient-derived xenograft (PDX) from a patient with
endocrine therapy-resistant disease. Limited functional characterization of ESR1-e6>YAP1 showed that the fusion protein
drove resistance to endocrine therapy and estradiol-independent proliferation. Herein we build on our original report by
contrasting the functional, transcriptional, and pharmacological
properties of the ESR1-e6>YAP1 fusion with additional ESR1
gene fusion events identified by RNA-seq of both early-stage
and metastatic ER+ breast cancers.
RESULTS
Identification and Verification of In-Frame ESR1 Gene
Fusions
A systematic screen was conducted to identify ESR1 translocations in three datasets: 728 primary breast tumors from The
Cancer Genome Atlas (TCGA) (Ciriello et al., 2015), 81 primary
breast cancers from two neoadjuvant aromatase inhibitor (AI)
clinical trials (Ellis et al., 2011; Olson et al., 2009), and 25 biopsy
samples from patients with late-stage ER+ breast cancer
(Figure 1A). From these analyses, 13 high-confidence ESR1
fusion transcripts were identified in 10 ER+ samples from the
TCGA dataset (Table S1). Five of these fusion events were
between ESR1 and CCDC170 and were recently reported (Veeraraghavan et al., 2014). Of these, only 1 CCDC170 out-of-frame
fusion included exon 5 (e5) of ESR1 (ESR1-e5>CCDC170),
thereby preserving sufficient ESR1 sequence to bind DNA. A single TCGA case displayed evidence for three ESR1 gene fusions:
(1) a PCR-validated ESR1-e6 fused in frame to C-terminal
sequences from AKAP12 (ESR1-e6>AKAP12) (Figure S1); (2) a
PCR-validated in-frame ESR1-e7 fusion involving the entire
coding sequence of POLH, a DNA polymerase in the xeroderma
pigmentosum gene family (ESR1-e7>POLH), and (3) an out-offrame ESR1-e4>CCDC170 fusion.
From an RNA-seq screen of 81 primary, treatment-naive, ER+
breast cancers from two neoadjuvant AI clinical trials (Table S1,

NeoAI Trials), two PCR-validated ESR1 fusions were identified.
The first was an in-frame fusion retaining the first six exons of
ESR1 (ESR1-e6) fused to C-terminal sequences of NOP2, a
nucleolar protein (ESR1-e6>NOP2). The second fusion identified
involved ESR1-e6 fused out of frame to AKR1D1, an aldo-keto
reductase family member (ESR1-e6>AKR1D1). In the datasets
of primary ER+ breast cancer examined, ESR1 fusion events
are relatively rare, occurring at 2% frequency. The majority of
these fusions are out of frame, and 42% of these fusion events
(8 of 19) include sufficient ESR1 exons to allow ESR1-specific
nuclear binding.
To investigate ESR1 fusion events in late-stage ER+ disease,
RNA-seq data from 25 biopsy samples obtained from patients
with advanced endocrine therapy refractory disease were examined (Table S1, Late Stage, and Table S2). These samples
included the ESR1-e6>YAP1 sample we originally described,
as it was drawn from this series (Li et al., 2013), and of these
25 samples, 2 harbored in-frame ESR1 fusion events. The
ESR1-e6>PCDH11X fusion was caused by ESR1-e6 fusion in
frame with C-terminal sequences of protocadherin 11X.
PCDH11X encodes for an atypical cell surface cadherin family
member. The sample was a chest wall recurrence from a
49-year-old man who presented with locally advanced ER+
breast cancer and experienced progression on tamoxifen, letrozole/leuprolide, and fulvestrant before the sample was accrued.
Of the eight identified ESR1 fusions from all datasets that were
PCR validated (Figure S1), only three in-frame fusions,
ESR1-e6>YAP1 and ESR1-e6>PCDH11X from advanced
disease and ESR1-e6>NOP2 from a primary tumor that showed
subsequent resistance to endocrine therapy, produced stable
proteins when expressed as cDNA, allowing further study
(Figure 1B). Expression of all three fusion partner genes were
highly expressed in patient tumors, as shown by expression
rank plots for YAP1, PCDH11X, and NOP2 translocation- bearing
tumors relative to the expression of these genes among TCGA
breast samples (Figure 1C). Relative RNA levels of transcripts
were analyzed for each fusion partner, which showed increases
in transcript levels beyond the fusion breakpoint for each gene
examined, confirming that the fusion partner was disproportionately expressed versus the non-translocated allele (Figure 2A).
In-Frame ESR1 Fusions from Endocrine-Refractory
Disease Confer Estrogen-Independent and FulvestrantResistant Growth of ER+ Breast Cancer Cells
To test whether examples of ESR1 in-frame gene fusions were
drivers of endocrine therapy resistance, each fusion was individually expressed in two ER+ breast cancer cell line models:
T47D and MCF7. Expression of fusion ER proteins in T47D cells
was similar or lower than that observed in the WHIM18 PDX
bearing the ESR1-e6>YAP1 fusion, indicating that phenotypic
conclusions are not based on excess expression (Figure 2B).
In addition, several out-of-frame CCDC170 and an AKR1D1
fusion event identified in this study (Table S1) were also engineered into T47D cells. Growth of ESR1 fusion-expressing
T47D was monitored in estradiol (E2)-deprived media and after
addition of E2. Both in-frame fusions from advanced disease,
ESR1-e6>YAP1 and ESR1-e6>PCDH11X, promoted estrogenindependent growth (Figure 2C, E2), but the primary tumor
Cell Reports 24, 1434–1444, August 7, 2018 1435
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Figure 1. Identification and Verification of ESR1 Fusions
(A) Circos plot depicting ESR1 fusion events from Table S1. In-frame ESR1 fusions are depicted with a red line, and out-of-frame ESR1 fusions depicted with a
blue line. Asterisks denote PCR-validated transcripts (Figure S1).
(B) Of eight ESR1 fusions identified in (A) that were PCR validated, only three ESR1 fusions produced stable, in-frame proteins (indicated in red): ESR1-e6>YAP1,
ESR1-e6>PCDH11X, and ESR1-e6>NOP2. Illustration depicting in-frame ESR1 fusions with ESR1 codon structure shown at the bottom. Non-coding exons (e)
1 and 2 are shown as white boxes, and gray boxes depict exons encoding domains shown above. Vertical line indicates shared break points after exon 6 of ESR1.
All depicted fusions retain exons encoding amino acids (aa) 1–365 of ER corresponding to the activation function 1 (AF1) domain, DNA-binding domain (DBD), the
hinge region that includes the nuclear localization domain, and part of the activation function 2 (AF2)/ligand-binding domain (LBD).
(C) RNA-seq determined rank-ordered expression of YAP1, PCDH11X, and NOP2 from 728 TCGA breast tumor samples, shown as colored circles according to
subtype. Triangles indicate ranked expression from indicated ESR1 fusion containing sample among the TCGA breast samples.
See also Figure S1.

fusion event, ESR1-e6>NOP2, had no growth-promoting properties. The out-of-frame events tested were also inactive (Figure S2A). E2 could stimulate growth in all conditions of fusion
construct expression (Figure 2C, compare +E2 and E2), suggesting that neither the ESR1 in-frame active fusions (ESR1e6>YAP1 and ESR1-e6>PCDH11X) nor the ESR1-e6 truncation, and not even the in-frame but inactive ESR1-e6>NOP2
fusion, could function as a dominant-negative on endogenous
ER. Cells were treated with fulvestrant to degrade endogenous
ER, while retaining expression of intact ESR1 fusions that
cannot bind drug or ligand, to test the specific contribution of
the fusions to E2-independent growth. As expected, endogenous ER was degraded by fulvestrant, whereas levels of
ESR1 fusion proteins, as well as an ESR1-e6 truncation
construct, were unaffected (Figure S2B), and growth promoted
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by ESR1-e6>YAP1 and ESR1-e6>PCDH11X was resistant to
fulvestrant treatment (Figure 2C, E2, +Fulvestrant). There
was lack of additional growth promotion by the fusions when
E2 was added in the presence of fulvestrant (Figure 2C,
compare +E2, +Fulvestrant and E2, +Fulvestrant). However,
under these same conditions (Figure 2C, +E2, +Fulvestrant),
growth induced by the YAP1 and PCDH11X fusions remains
significantly greater than controls (YFP and ESR1-WT [wildtype]). These results were confirmed in a second ER+ breast
cancer cell line, MCF7 (Figures S2C–S2D). The NOP2 fusion
was highly expressed in the MCF7 cell line, in contrast to
NOP2 fusion-expressing T47D, but still lacked growth-promoting activity in hormone-deprived conditions, confirming that
absence of functional effects was not due to inadequate
expression of the NOP2 fusion.
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Figure 2. In-Frame ESR1 Fusions from Endocrine-Refractory Disease Confer Estrogen-Independent and Fulvestrant-Resistant Growth of
ER+ Breast Cancer Cells
(A) RNA-seq mapped read depth was calculated across YAP1, PCDH11X, and NOP2 genes in corresponding fusion containing tumors. Red line indicates fusion
breakpoints.
(B) Immunoblotting with an N-terminal ER antibody in hormone-deprived stable T47D and WHIM18 PDX. Asterisks indicate ER fusion.
(C) Cell proliferation studies of hormone-deprived stable T47D cells (E2), after fulvestrant treatment (E2, +Fulvestrant), after E2 stimulation (+E2), or after
E2 stimulation with fulvestrant treatment (+E2, +Fulvestrant). Bar graphs show average ± SEM from three independent experiments. ****p < 0.0001 and
####p < 0.0001 as described in STAR Methods.
(D) Box and whisker plots show tumor volumes of T47D xenograft tumors grown with (+E2) or without E2 supplementation (E2). Boxes depict interquartile range,
center line represents median, and whiskers extend to minimum and maximum values for each group (n = 6). p values show significance comparing YFP E2 to all
other groups.
See also Figure S2.

The ability of the three ESR1-e6-containing in-frame fusions
to induce estrogen-independent growth was further tested
in vivo in a xenograft study with stable T47D cells without supplementary E2. As controls, T47D YFP cells were used with supplementary E2. Results showed that control YFP E2 cells produced negligible tumor growth compared with YFP cells +E2
(Figure 2D). However, T47D cells expressing YAP1 and
PCDH11X in-frame ESR1 fusions formed tumors significantly
larger than YFP E2, while the cells expressing the NOP2 fusion
did not (Figure 2D).
Active ESR1 Fusions Promote Estrogen-Independent
Gene Expression
To explore transcriptional properties associated with the ESR1
fusion proteins described above, genome-wide binding of
HA-tagged ESR1 fusions was examined by HA chromatin
immunoprecipitation followed by next-generation sequencing

(ChIP-seq) in hormone-deprived stable T47D. ChIP-seq identified
445 binding regions shared by ESR1-WT, ESR1-e6>YAP1, and
ESR1-e6>PCDH11X (Figure 3A). Very few sites were bound by
ESR1-e6>NOP2 fusion despite high expression of HA-tagged
NOP2 fusion (Figure S3E), supporting earlier observations of inactivity in functional studies (Figures 2C, 2D, and S2C). ChIP-qPCR
confirmed recruitment of ER to regulatory regions of known
estrogen-responsive genes in a ligand-dependent manner in cells
expressing WT-ER (Figure 3B). Additionally, both YAP1 and
PCDH11X fusions showed estrogen-independent enrichment at
regulatory regions of established estrogen-responsive genes.
For example, both fusions were enriched at the promoter of a canonical ER-regulated gene, GREB1, and the PDCH11X fusion was
also enriched at enhancer estrogen response elements (EREs) of
TFF1 and PGR (Figure 3B).
To investigate whether expression from genes bound by ESR1
fusions was modulated, RNA-seq was performed. Hierarchical
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Figure 3. Active ESR1 Fusions Promote Estrogen-Independent Expression of Target
Genes

B

D

clustering was conducted on differentially expressed genes
near 445 shared sites bound by ESR1-WT, YAP1, and
PCDH11X fusions, as indicated by the ChIP-seq data (Figure 3C). Upon stimulation with E2, the expression pattern of
YFP control cells clustered away from unstimulated YFP cells,
with enrichment for differential expression of estrogen-responsive genes. The YAP1 and PCDH11X fusion-expressing cells
had expression patterns that clustered together under estrogen-deprived and stimulated conditions and with E2-stimulated
YFP cells. The transcriptionally active ESR1 fusions maintained
expression of estrogen-regulated genes in low-estrogen
conditions at levels observed in YFP control cells in the
presence of E2, demonstrating strong estrogen-independent
gene activation. mRNA-qPCR validation of GREB1, TFF1,
and PGR expression confirmed estrogen-independent and
fulvestrant-resistant gene regulation (Figures 3D and S3F), suggesting that the active ESR1 fusions drive endocrine resistance
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(A) Venn diagram depicting overlap of binding sites
from hormone-deprived stable T47D cells expressing HA-tagged ESR1 constructs identified by
HA-ChIP-seq.
(B) HA-ChIP followed by qPCR for ER-binding
regions of ER-responsive genes and negative ERbinding region. Bar graphs show average values
from three experiments ± SEM. Asterisks denote
significant differences as described in STAR
Methods.
(C) Heatmap showing differentially expressed
genes near 445 sites bound by ESR1-e6>YAP1,
ESR1-e6>PCDH11X, and ESR1-WT identified in
(A). Known ER-responsive genes are indicated
(CTSD, GREB1, PGR, TFF1, and PDZK1). Scale
bar indicates row Z score.
(D) Bar graphs depicting relative fold changes
of estrogen-responsive genes whose ER-binding
regions were examined in (B) from hormonedeprived stable T47D cells, normalized to
YFP E2 (dark blue bar), after E2 addition (+E2,
red bar), or in combination with fulvestrant (light
blue and pink bars). E2 and +E2 for ESR1 fusionexpressing cells have been omitted for clarity; see
Figure S3F for complete data. Data are shown as
averages from two independent experiments ±
SEM.
See also Figure S3.

in a canonical manner through EREdependent activation. Moreover, the
estrogen-independent activity of the
YAP1 and PCDH11X fusions was also
independent of endogenous WT-ER, as
transcriptional activity was maintained
after cells were treated with fulvestrant
to degrade endogenous ER. Thus, functionally important heterodimer formation
between ESR1 fusion protein and
WT-ER is not likely. This conclusion
was also supported by the lack of ESR1 fusion association
with WT-ER in a co-immunoprecipitation assay (Figure S3D).
In contrast, the ESR1-e6 truncation mutant and NOP2 fusion
clustered together with YFP control cells displaying similar patterns of ligand-dependent ER gene expression, supporting our
earlier observations that the NOP2 fusion lacks ability to bind a
large repertoire of EREs but whose inactivity is not due to mislocalization outside the nucleus, as staining for HA-tagged
ESR1 fusions constructs demonstrated nuclear localization
(Figure S3A). These data were further supported by ERE-luciferase reporter experiments in HEK293T cells (Figure S3B).
ESR1-WT drove estrogen-dependent expression of the EREluciferase reporter. In contrast, both ESR1-e6>YAP1 and
ESR1-e6>PCDH11X as well as the ESR1-Y537S activating
mutant drove estrogen-independent expression of the EREluciferase reporter. The level of activation by ESR1-e6>YAP1
was substantially higher than ESR1-e6> PCDH11X, which
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H

Figure 4. Active ESR1 Fusions Promote Metastasis by Upregulating an EMT-like Transcriptional Program
(A) Heatmap depicting genes upregulated by ESR1-e6>YAP1 and ESR1-e6>PCDH11X versus YFP and ESR1-e6>NOP2 (from bottom of Figure 3C). Scale bar
indicates row Z score.
(B) GSEA using genes identified in (A).
(C) Bar graphs depicting expression of SNAI1 and VCAN, by mRNA-qPCR in hormone-deprived stable T47D cells (E2). Values are normalized to YFP E2 (dark
blue bar), treated with E2 (+E2, red bar), and in combination with fulvestrant (light blue and pink bars). E2 and +E2 conditions for all cell lines are shown in
Figure S4B. Data are averages of two independent experiments ± SEM.
(D) Immunoblotting for endogenous ER (ER) and ER fusion (asterisks) using an N-terminal ERa antibody, Snail, and E-cadherin in hormone-deprived stable T47D
and MCF7 cells. Vertical line in E-cadherin blot indicates different exposures taken for T47D and MCF7.
(E) Scratch wound healing assay images of hormone-deprived stable T47D at 0 and 72 hr post-wounding. Dotted black line indicates leading edge of cells. Scale
bar, 300 mm.

(legend continued on next page)
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had activity intermediate to that achieved by the constitutively active ESR1-Y537S mutant and ESR1-e6>YAP1 (Li
et al., 2013). In contrast to the ESR1-e6>YAP1 and ESR1e6>PCDH11X fusions, neither the ESR1-e6 truncation
mutation nor the ESR1-e6>NOP2 fusion drove expression of
the ERE reporter. The transcriptional inactivity of the NOP2
fusion was not due to abrogation of ERE binding, as pulldown experiments with a biotinylated concatenated ERE probe
with a mutant ERE as a control demonstrated sequence-specific binding for all in-frame fusions (Figure S3C). In summary,
our observations suggest that the inactivity of the NOP2 fusion
may be due to a failure to access chromatin in the nucleus of
intact cells, rather than an inability to bind DNA per se.
Active ESR1 Fusions Promote Metastasis by
Upregulating an EMT-like Transcriptional Program
A cluster of genes was identified that was selectively upregulated by the active YAP1 and PCDH11X fusions (Figures 3C
and 4A). Gene set enrichment analysis (GSEA) was used to
examine pathway enrichment in this cluster, which indicated
significant enrichment of estrogen response pathways as well
as an epithelial-to-mesenchymal transition (EMT)-like signature
(Figure 4B). The EMT signature included TGM2, COL3A1,
INHBA, and VCAN. One of the best-described EMT genes,
SNAI1, was also selectively upregulated by both active fusions.
Analysis of binding site distances to transcription start sites
(TSSs) of genes in this cluster demonstrated that the majority
of binding occurs at distances >50 kb from the TSS (Table S3).
This suggests a propensity of the active YAP1 and PCDH11X
fusions to bind in enhancer regions upstream and downstream
of these genes, characteristic of the ER cistrome reported in
the literature (Carroll et al., 2006). Motif analysis of these binding
sites showed enrichment for the ERE motif (Figure S4A), suggesting that the direct regulation of EMT genes by the active
YAP1 and PCDH11X fusions is mediated by enhancer and
more distant range interactions. Upregulation of VCAN and
SNAI1 transcripts (Figures 4C and S4B) and Snail protein
(Figure 4D) was orthogonally validated. In MCF7 cells, whose
basal levels of Snail were higher in YFP controls compared
with T47D YFP, showed an induction of Snail by ESR1e6>YAP1, but not by ESR1-e6>PCDH11X, suggesting a degree
of cell context-dependent effects (Figure 4D). Upregulation of
Snail protein was also confirmed in T47D xenograft tumors and
in a PDX model naturally harboring the ESR1-e6>YAP1 fusion
(WHIM18) (Figure 4G). Expression of SNAI1 was unaffected by
fulvestrant treatment in T47D cells, consistent with the conclusion that upregulation of EMT genes by the active fusions is independent of endogenous WT-ER (Figures 4C and S4B).
ChIP-seq also identified 71 selectively bound sites by ESR1e6>YAP1 and ESR1-e6>PCDH11X not bound by ESR1-WT nor

ESR1-e6>NOP2 (Figure S4C). GSEA pathway analysis of differentially expressed genes near these sites showed enrichment for
UV radiation response genes, as well as enrichment for EMT
genes, with TGFBR3 and GJA1 contributing to EMT pathway
enrichment (Figure S4C). TGFBR3 encodes for transforming
growth factor-b receptor III and has roles in migration and invasion (Gatza et al., 2010). GJA1 encodes for connexin-43, a gap
junction protein whose expression in breast cancer cells has
been implicated in pulmonary metastasis (Elzarrad et al.,
2008), consistent with observed lung metastasis in both patients
from which the ESR1-e6>YAP1 and ESR1-e6>PCDH11X fusions
were identified.
A decrease in E-cadherin levels from YAP1 and PCDH11X
fusion-expressing cells was observed relative to YFP control
and NOP2 fusion-expressing cells (Figure 4D), and a decrease
in cell surface E-cadherin was also observed, consistent with
an EMT-like transition (Figures S4E and S4F). However, there
was no detectable increase in vimentin levels, suggesting that
the YAP1 and PCDH11X fusions drive a partial EMT gene
expression pattern that nonetheless can be metastasis associated (Jolly et al., 2015). To examine the functional consequences
of the active fusions with respect to the metastatic process, cell
motility was examined. The YAP1 and PCDH11X fusions induced
significantly greater wound recovery and motility than YFP
controls and NOP2 fusion-expressing cells (Figure 4E, quantified
in Figure S4D). To exclude the possibility that EMT-associated
gene expression was due to phenotypic drift of cells under
long-term selection, small interfering RNA (siRNA)-mediated
knockdown of ESR1-e6>YAP1 fusion was examined to
determine whether EMT-associated features could be reversed.
Estrogen-deprived stable T47D YFP control or ESR1-e6>YAP1expressing cells were pre-treated with fulvestrant to degrade
endogenous WT-ER, before transfecting with negative control
siRNA (siESR1) or siESR1 against the N terminus of ESR1
(siESR1+). Forty-eight hours post-transfection, Snail protein
levels were markedly reduced in ESR1-e6>YAP1 cells after
siESR1 transfection with or without fulvestrant pre-treatment
compared with siESR1 with or without fulvestrant (Figure 4F,
compare lanes 5 and 7 with lanes 6 and 8). In addition, cells
with decreased Snail as a result of ER-YAP1 fusion protein
knockdown tended to have higher levels of E-cadherin, suggesting that knockdown of the ESR1-e6>YAP1 fusion transcript
restores these aspects of a typical epithelial gene expression
pattern. Similar effects were confirmed in stable MCF7 cells expressing ESR1-e6>YAP1 (Figure S4G, compare lanes 5 and 7
with lanes 6 and 8), although Snail levels were more affected
by fulvestrant pre-treatment alone, showing that higher basal
levels of Snail in MCF7 cells can also be driven by WT ESR1 (Figure S4G, compare lanes 1 and 3 for YFP-expressing cells and
lanes 5 and 7 for ESR1-e6>YAP1-expressing cells). However,

(F) Immunoblotting of hormone-deprived T47D cells pre-treated with vehicle (Fulv) or fulvestrant (Fulv+) before transfecting negative control siRNA (siRNA) or
siRNA against the N terminus of ESR1 (siESR1+).
(G) Immunoblotting for Snail in T47D xenograft and WHIM18 PDX tumors.
(H) ER IHC images performed on lungs of mice bearing T47D xenografted tumors from Figure 2D. Box and whiskers plots show IHC quantification of ER+ cells,
with boxes depicting interquartile range, center line representing median value, and whiskers extending to minimum and maximum values for each group (n = 5).
p values indicate significance comparing YFP –E2 versus fusion-bearing groups or versus YFP +E2. Scale bar, 100 mm.
See also Figure S4 and Table S3.
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Snail expression is resistant to fulvestrant suppression in the
presence of the ESR1-e6>YAP1 fusion (Figure S4G, compare
lanes 3 and 7). The metastatic potential of fusion-expressing
cells in vivo was measured by ER immunohistochemistry from
the lungs, liver, and bones of mice bearing T47D xenografts
from Figure 2D. The number of micrometastatic ER+ cells in
the lungs of YAP1 and PCDH11X fusion bearing mice was significantly greater than that in the lungs of mice bearing tumors
generated from YFP control cells upon estrogen deprivation (Figure 4H). YFP control tumors grown with E2 supplementation
were much larger (Figure 2D), but pulmonary micrometastasis
was not significantly different from YFP controls E2, demonstrating that differences in pulmonary metastasis potential associated with the active fusions were not due simply to differences
in disease burden. Bone and hepatic micrometastases were not
observed. Pulmonary metastasis in this model was not a feature
of YFP control cells, even when disease burden was increased
markedly with E2 supplementation. Taken together, these
results suggest a role for active YAP1 and PCDH11X fusions in
driving pulmonary metastasis in association with the expression
of genes known to contribute to EMT biology and metastatic
behavior.
Growth Driven by ESR1 Fusions Can Be Suppressed with
CDK4/6 Inhibitor Treatment
The loss of the LBD renders the function of ESR1 fusion genes
resistant to all endocrine treatments, and therefore alternative
therapies will be necessary to treat patients who present with
active ESR1 fusions. Palbociclib, a selective CDK4/6 inhibitor
was chosen for study because of our recent report that this agent
can antagonize the growth of tumors expressing ESR1 mutations
as long as phospho-Rb (pRb) is present (Wardell et al., 2015).
Because the target of activated CDK4/6 is Rb, pRb levels were
examined by immunohistochemistry (IHC) in ESR1 fusion-expressing T47D xenograft tumor sections (Figure S5A). pRb levels
in YAP1 and PCDH11X fusion xenograft tumors grown without E2
supplementation were comparable with YFP controls +E2 and
were elevated relative to YFP E2 and NOP2 fusion-containing
tumors. T47D stable cells expressing YFP and the three in-frame
ESR1 fusions were treated with palbociclib under hormonedeprived conditions and growth-inhibitory effects were assessed
(Figure 5A). Palbociclib inhibited T47D cell growth driven by the
YAP1 and PCDH11X fusions in a dose-dependent manner. A
similar palbociclib effect was observed in ESR1 fusion-expressing MCF7 stable cells (Figure S5B). To test palbociclib sensitivity
in vivo, a PDX model naturally harboring the ESR1-e6>YAP1
fusion (WHIM18) was exposed to palbociclib. Consistent with
in vitro results, tumor growth in the PDX model was inhibited in
mice treated with palbociclib compared with vehicle-treated
mice (Figure 5B; tumor growth rates shown in Figure S5C). Palbociclib-treated WHIM18 tumors also showed significant reduction
in pRb and marked decrease in Ki-67 levels, without altering
levels of ER (Figure 5C) or progesterone receptor (PR) (Figure S5D). Areas containing micrometastatic ER+ cells observed
in the lungs of vehicle chow-treated WHIM18 mice were not
seen in palbociclib-treated mice (Figure 5D), suggesting that pulmonary metastatic frequency could also be downregulated by
CDK4/6 inhibition.

DISCUSSION
This study demonstrated that two in-frame ESR1 fusions in a
small late-stage cohort of metastatic ER+ cases drive not only
endocrine therapy resistance but also metastatic disease
progression. The functional characterization of ESR1 fusions’
properties described herein should drive efforts to identify and
further characterize additional ESR1 fusions in early- and latestage ER+ breast cancer.
The ability to block active ESR1 fusion-induced growth with a
CDK4/6 inhibitor has important implications for clinical practice.
Patients with active ESR1 fusions may present with a clinical
pattern of rapidly progressing disease despite adjuvant or
metastatic endocrine therapy treatment and therefore be
offered chemotherapy instead of a CDK4/6 inhibitor-containing
regimen. Because therapeutically resistant disease is infrequently re-biopsied and even more rarely analyzed using
RNA-seq, a prospective study of ESR1 in-frame fusion-expressing ER+ tumors will be required to establish an effective
approach for these tumors.
Although ESR1 fusions are challenging to diagnose because
of variable 30 fusion partners, evidence for additional ESR1
fusions is emerging in the literature. For example, ESR1e6>DAB2 and ESR1-e6>GYG1 were both identified in metastatic ER+ breast cancer (Hartmaier et al., 2018). Like the active
ESR1 fusions we describe herein, ESR1-e6>DAB2 and ESR1e6>GYG1 follow the same pattern (i.e., ESR1 exon 6 in-frame fusions with 30 partners provided by inter-chromosomal translocation). Thus, this type of ESR1 fusion gene structure is most
clearly linked to endocrine therapy resistance. Several precision
medicine programs now include RNA-seq in their standard pipelines, and thus much more data on ESR1-e6 in-frame fusion
prevalence should be available soon.
Because active ESR1 fusions induce pRb (Figure S5A), pRb
might also be an appropriate marker to guide CDK4/6 inhibitor
therapy and might provide strong pre-clinical rationale to potentially examine pRb levels in patients on AIs to define populations
for CDK4/6 inhibition. This idea is supported by our previous
report, in which the growth of endocrine-refractory PDX tumors
remained sensitive to CDK4/6 inhibition, as long as those tumors
express pRb under estrogen-deprived growth conditions (Wardell et al., 2015).
The inactivity of the ESR1-e6>NOP2 fusion is surprising, as
the expressed recombinant protein is stable. This demonstrates
that not every in-frame ESR1-e6 fusion is active with respect to
endocrine therapy resistance. The NOP2 fusion may have other
biological properties that we were unable to detect in our experimental model systems. The out-of-frame ESR1 fusions also had
no growth-promoting properties but could also be active though
novel mechanisms.
The role of active ESR1 fusions in promoting EMT-like gene
expression changes follows a pattern associated with other
members from a diverse family of cancer-associated gene fusion
events. For example, the TMPRSS2-ERG fusion in prostate cancer has also been reported to directly regulate cell migration
genes (Tian et al., 2014). Given the diverse structures of
EMT-inducing ESR1 fusions revealed here with the study of
just two, it is also possible that more EMT and motility-inducing
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Figure 5. Growth Driven by ESR1 Fusions Can Be Suppressed with CDK4/6 Inhibitor Treatment
(A) Growth of hormone-deprived stable T47D cells in response to increasing concentrations of a CDK4/6 inhibitor, palbociclib. YFP +E2 used as control. P value
describes significance between YFP +E2, ESR1-e6>YAP1, and ESR1-e6>PCDH11x slopes compared with YFP E2. Data shown are averages of three
independent experiments ± SEM.
(B) Tumor volumes of WHIM18 PDX in the absence of exogenous E2 supplementation. Arrow indicates treatment start (Tx) with vehicle or palbociclib containing
chow. P value describes significance of tumor growth rates (slopes) derived from tumor volumes at day of randomization to experiment end. Data are shown as
averages from 8–11 mice per treatment group ± SEM.
(C) Representative IHC images for ER, pRb, and Ki-67 from vehicle and palbociclib-treated WHIM18 tumors. Quantification of IHC staining below with significance comparing treatment groups. Data are averages counts from five tumor sections from each treatment group, with error bars representing SD.
(D) ER IHC images of lungs from WHIM18-bearing mice. Micrometastatic ER+ lesions were quantified by measuring area of ER+ cells. Data are shown as average
ER+ areas from five lung sections per treatment group. P value determined as in (C). Scale bar, 100 mm in (C) and (D).
See also Figure S5.

transcription factor gene fusions remain to be discovered, and
the formation of these could be primary drivers of metastasis.
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Ellis (mjellis@bcm.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
All cell lines were purchased from ATCC and cultured at 37 C in 5% CO2. All cell lines were authenticated and tested for mycoplasma.
HEK293T and MDA-MB-231 cells were cultured in DMEM with L-Glutamine and 4.5 g/L glucose (HyClone) supplemented with 10%
FBS (cat# F0926, Sigma) and 1% penicillin-streptomycin (Invitrogen). T47D and MCF7 cells were cultured in RPMI1640 with L-Glutamine (Mediatech) supplemented with 10% FBS, glucose to 4.5 g/L (Sigma), 10 mM HEPES (GenDEPOT), 1 mM sodium pyruvate
(GenDEPOT), and 50 mg/mL gentamycin (GenDEPOT). Estrogen/hormone deprivation was performed by plating cells in culturing
media overnight followed by washing with PBS and replacing with hormone deprived media consistaing of phenol red free media
supplemented as described above but with 10% charcoal-stripped serum (CSS) (cat# F6765, Sigma), followed by changing with hormone-deprived media every 2-3 days for 5-7 days.
In Vivo Animal Studies
All animal experiments were carried out in strict accordance with the guidelines recommended for care and use of laboratory animals
by the National Institutes of Health. The Animal Studies Committee at Washington University (St. Louis, MO, USA) approved all animal
protocols used for T47D xenograft studies. Three-week old NOD/SCID gamma female mice were purchased from Jackson Laboratories. Stable T47D cells were trypsinized, counted, washed by PBS, and suspended in ice cold serum free RPMI medium at 10 3 106
cells per 100 mL. Matrigel was added to a final 33% by volume. 150 mL mix (10x106 cells) was injected subcutaneously into the mouse
flanks bilaterally. Six mice were injected per group. Tumor volumes were measured by caliper weekly. For PDX studies, all animal
procedures were approved by the Institutional Animal Care and Use Committee at Baylor College of Medicine (Houston, TX, USA)
(protocol# AN-6934). 2-3 mm tumor pieces from a second generation growing WHIM18 tumor were engrafted into cleared mammary
fat pads of 3-4 weeks old SCID/bg mice (Charles River) and allowed to grow without exogenous E2 supplementation until tumors
reached 150-400 mm3. Mice were then randomized to receive vehicle or palbociclib (Pfzier) containing chow (daily dose of
70mg/kg per day) for an additional 30 days (11 mice per group). Tumor volumes were measured by caliper every 3-4 days. For all
animal experiments, tumor volumes were calculated by V = 4/3 3 p 3 (length/2)2 3 (width/2). Animals were sacrificed when tumors
reached 1500 mm3 or at the study end time point. Tumors and organs were harvested and frozen in liquid nitrogen for storage or fixed
in 4% formaldehyde overnight at RT, then held in 70% ethanol before paraffin embedding, sectioning (5 mm) and subsequent IHC
processing.
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Clinical Samples
The primary breast cancer samples for this study were either accrued from two neoadjuvant endocrine therapy trials (Ellis et al., 2011;
Olson et al., 2009) or analyzed from TCGA breast samples (Ciriello et al., 2015). The methodologies for RNA extraction and expression
profiling experiments have been previously published (Ellis et al., 2011). Frozen metastatic biopsy samples from patients with
advanced breast cancer (Table S2) were accrued under a banking protocol approved by the Washington University School of Medicine Institutional Review Board (approval number 201102244).
METHOD DETAILS
ESR1 Fusion Discovery Using ChimeraScan and INTEGRATE
Fusion candidates were discovered using ChimeraScan (Iyer et al., 2011) and INTEGRATE (Zhang et al., 2016) when whole genome
sequencing data were available from 38 cases previously reported (Ellis et al., 2012). The Illumina RNA-Seq paired-end reads in
FASTQ format were provided to ChimeraScan version 0.4.5, which was run using default parameters. The alignments (BAM format
by TopHat2) of the RNA-seq reads are provided to INTEGRATE version 0.1, which is run using default parameters in RNA only mode.
All the analysis was based on hg19. ChimeraScan results (bedpe format) are filtered by removing records with types marked as read
through, overlapping converging, overlapping diverging, adjacent converging, and adjacent diverging. These could be transcriptome
only variations or chimeras reported because of certain annotation issues. The gene fusions with ESR1 gene as a fusion partner are
picked out from all the fusion candidates discovered by the methods described above and from analysis done by TCGA.
Molecular Cloning to Generate ESR1 Fusion Constructs
cDNAs encoding ESR1-e6>NOP2, ESR1-e6>PCDH11X, and ESR1-e6>AKR1D1 were synthesized from patient RNAs via oligo-dT
reverse transcription (RT) followed by polymerase chain reaction (PCR) using primers complementary to the 50 and 30 ends of the
fusion genes. ESR1-e7>POLH and ESR1-e6>AKAP12 were generated from cDNAs encoding ESR1, POLH, and AKAP12 by overlapping PCR extension/amplification as previously described for ESR1-e6>YAP1 (Li et al., 2013). All other constructs were created
by standard PCR using pre-existing cDNA templates. Amplified DNA fragments were inserted into the lentiviral vector pFLRu-FH as
described previously (Li et al., 2013). ESR1-e6>AKAP12 was generated but due to its exceptionally large size, could not be cloned
into the lentiviral vector and subsequently proved hard to express upon transfection and was not studied further. Carboxy-terminal
HA-tagged ESR1 fusion constructs were generated by subcloning each construct from pFLRu-FH using primers for PCR that
included BamHI and EcoRI restriction sites along with the HA sequence (STAR METHODS) into pCDH-CMV-MCS-EF1a-RFPPuro vector (System Biosciences). All constructs in their final vectors were confirmed by Sanger sequencing.
Lentiviral Production and Stable Cell Line Generation
Lentiviral production was performed as described previously (Li et al., 2013). Briefly, ESR1 constructs cloned in pFLRu-FH and HAtagged ESR1 constructs in pCDH-CMV-MCS-EF1a-RFP-Puro (System Biosciences) and pCDH-CMV-MCS-ER1a-Puro (System
Biosciences) vector DNAs were co-transfected with the packaging plasmids into HEK293T cells using Fugene HD (Roche). Culture
media containing viruses were harvested after 48 hr, filtered, and added to T47D and MCF7 cells in the presence of polybrene. Stably
infected cells were selected by 2 mg/mL puromycin (Sigma) two days after infection. Three sets of T47D stable cell lines were generated, one set expressing non-HA-tagged ESR1 constructs (used in Figures 2, S2, 4G, 4H, 5A, and S5A), one set expressing
HA-tagged ESR1 constructs in pCDH-CMV-MCS-EF1a-RFP-Puro (used in Figures 3, S3D–S3F, 4A–4F, and S4A–S4F) and one
set expressing HA-tagged ESR1 constructs in pCDH-CMV-MCS-ER1a-Puro used in Figure S3A. Two sets of MCF7 cells were generated, one set expressing non-HA-tagged ESR1 constructs (used in Figures S2C, S2D, and S5B) and HA-tagged ESR1 constructs in
pCDH-CMV-MCS-ER1a-Puro (used in Figures 4D and S4G).
In Vitro Growth Assays
Hormone independent cell growth was subsequently measured by low density triplicate plating of T47D or MCF7 cell lines in hormone-deprived media in 96-well plates (2000 cells/well) in the absence or presence of 10 nM E2 (Sigma) in combination without
or with 10 nM fulvestrant (Selleckchem). Cell growth was quantified by Alamarblue assay at Day 1 and Day 12 post plating and relative
growth was calculated as Day 12/Day 1 ratios. Remaining cells not used in the Alamarblue assay were plated in CSS containing media and grown further for 72h in the absence or presence of 10 nM fulvestrant before harvesting and subsequent processing for
immunoblot analysis. For palbociclib sensitivity assays, T47D and MCF7 cells were hormone deprived for seven days, then plated
in 96-well plates as described above in the absence of presence of 3-fold dilutions of palbociclib (cat# S1116, Selleckchem) from
10 mM down to 0.0015 mM for 12 days, changing hormone-deprived media and palbociclib every 2-3 days. Cell growth was quantified
similarly as above and relative growth was calculated by taking the palbociclib treated Day 12/Day 1 ratio divided by the vehicle
treated Day 12/Day 1 ratio.
siRNA Knockdown
Stable T47D or MCF7 were hormone-deprived for 7-9 days before pre-treatment with DMSO vehicle or 1 mM fulvestrant for 24h prior
to reverse transfection with RNAiMAX (Invitrogen) and 50 nM siRNA Universal Negative Control #1 (cat# SIC001, Sigma) or 50 nM
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siESR1 targeting N-terminal sequences of ESR1 (Sigma). Fresh DMSO or 1 mM fulvestrant was added during the transfection. 48h
post transfection, cells were collected by scraping and subjected to immunoblotting.
Immunoprecipitation and Immunoblot Analysis
For IP assays, hormone deprived stable T47D cells were left untreated or stimulated with 10 nM E2 for 15’ at 37 C. Cells were harvested then lysed in IP lysis buffer [0.5% NP-40, 10% glycerol, 280 mM NaCl, 50 mM Tris pH 8.0, 2 mM EGTA, 0.2 mM EDTA, 1 mM
PMSF, 1 mM sodium orthovanadate, 1 mM DTT, 1 mg/mL pepstatin, phosSTOP phosphatase inhibitor tablet (Roche), and cOmplete
EDTA-free protease inhibitor tablet (Roche)] for 20 min. 0.5 mg of clarified lysates were immunoprecipitated with an Anti-HA antibody
(cat# 3724, Cell Signaling, 1:50) overnight at 4 C with rotation. Protein A magnetic beads (cat# 1614013, Bio-Rad) were added and
rotated for 1h at 4 C followed by extensive washing with IP lysis buffer. Immunoprecipitated samples along with 25 mg of whole cell
lysates (inputs) were heated at 90 C before loading onto SDS-PAGE gels (Invitrogen) and electroblotted onto nitrocellulose membranes (Bio-Rad). Whole cell lyates for all other immunoblotting procedures were prepared in RIPA buffer and blotted as described
previously (Li et al., 2013). Fresh frozen WHIM18 tumors were cryopulverized (Covaris CP02) then lysed in RIPA buffer. The following
primary antibodies were used for blotting: N-terminal estrogen receptor a (cat# 04-820, Millipore, 1:1000), C-terminal estrogen receptor a (cat# sc-543, Santa Cruz, 1:1000), E-Cadherin (cat#14472, Cell Signaling, 1:1000), and Snail (cat #3879, Cell Signaling,
1:500). b-Actin (cat# A5316, Sigma, 1:5000) used as loading control for all immunoblots.
Dual Luciferase ERE Reporter Assay
To test ER fusion effect on wild-type ERE activation ability, 60 ng of empty pCDH-CMV-MCS-ER1a-Puro Vector, ESR1-WT-HA,
ESR1-e6>YAP1-HA, ESR1-e6>PCDH11X-HA, ESR1-e6>NOP2-HA, ESR1-e6-HA, or ESR1-Y537S-HA were co-transfected by
reverse transfection using Lipofectamine 2000 (Invitrogen) together with 25,000 hormone-deprived HEK293T cells per well in triplicates in a 96-well plate with 60 ng Firefly luciferase reporter vector (driven by three copies of vitellogenin Estrogen Response Element
(11354, Addgene) (Hall and McDonnell, 1999) and 5 ng control Renilla luciferase vector (pGL4.70, Promega). Prior to transfection,
HEK293T cells were cultured in hormone deprived media containing charcoal-stripped serum for seven days. One day after transfection, cells were either left unstimulated or stimulated with 2.5 nM E2 for 24h. On the following day, cells were quantified for the
firefly and Renilla luciferase levels using the Dual-Glo Luciferase assay kit (Promega). Averages of Firefly/Renilla luminescence readings from each sample were calculated and expressed as fold change in activity relative to Vector transfected –E2.
Biotinylated 3X ERE Pulldown
All 50 biotinylated DNA were synthesized by Integrated DNA Technologies. The sequence of the wild-type and mutant 3XERE were
GTAGGTCACTGTGACCTAGACGCAGGTCACTGTGACCTAGACGCAGGTCACTGTGACCGT and GTAGATCACTGTGAACTAGA
CGCAGATCACTGTGAACTAGACGCAGATCACTGTGAACGT, respectively. Each DNA and its complement were annealed by boiling
at 95 C for 15 min and allowed to cool overnight at room temperature. Each biotinylated DNA was bound to streptavidin M-280 Dynabeads (Invitrogen) per manufacturer’s directions and washed with NETN buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 0.5mM EDTA,
and 0.5% NP-40) before incubation with 200-1000 mg of HEK293T extracts (whole cell or nuclear extracts) transiently transfected with
the indicated expression constructs. Protein/DNA extracts were rotated at 4 C for 1h then washed four times with NETN buffer and
analyzed by immunoblotting.
ChIP-seq
Chromatin preparation
Stable T47D cells were hormone deprived for 7 days in charcoal-stripped containing media before fixing at 1% formaldehyde
(cat# F8775, Sigma) while swirling for 10 min at RT. To quench, glycine was added to 0.2 M and incubated for another 5 min at
RT. Cells were then washed and harvested in cold TBSE (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA). After further washing
in TBSE, cells were lysed in 0.1% SDS buffer (50 mM HEPES-KOH pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium
deoxcholate, 0.1% SDS, cOmplete EDTA-free protease inhibitor cocktail tablet) for 15 min at 4 C with rotation. Samples were centrifuged and washed 3X with 0.1% SDS buffer and resultant nuclear pellets were lysed with 1% SDS buffer for 15 min at 4 C with rotation. After washing with 0.1% SDS buffer, nuclear lysates were centrifuged at 20,000 rpm and resultant chromatin pellets were
resuspended in 0.1% SDS buffer with 0.5 mm glass beads (cat# 11079105, Biospec). The chromatin solution was sonicated with
a Branson Sonifier S450D with 18, 30 s pulses at 40% amplitude. Crosslinks were reversed by incubating sonicated chromatin
with pronase (Roche) at 42 C for 2h followed by incubation at 67 C for 6h. Phenol:chloroform (Ambion) extraction was used to isolate
sonicated chromatin that contained DNA fragments 200-500 bp in size that was confirmed by agrose gel electrophoresis.
Chromatin immunoprecipitation
Dynabeads Protein G (ThermoFisher) were equilibrated in 0.1% SDS buffer then a portion was added to chromatin extracts from
above to pre-clear for 2h at 4 C with rotation. HA antibody (cat# sc-7392, Santa Cruz) was added to the remaining Protein G and
allowed to bind for 2h at 4 C with rotation. Pre-cleared chromatin extracts were then added to antibody-bound beads and rotated
overnight at 4 C followed by extensive 5 min washes 0.1% SDS buffer, then once in 0.1% SDS buffer containing 0.35 M NaCl, then
once in ChIP wash buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 1 mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate), then once in
TE buffer. Elution was performed by pelleting and resuspending in ChIP buffer and heating at 68 C for 1h with agitation. Samples

e4 Cell Reports 24, 1434–1444.e1–e7, August 7, 2018

were pelleted, reuspended in TE buffer and crosslinks were reversed with pronase and heating at 42 C for 2h followed by incubation
at 67 C overnight. Chromatin isolation was then performed using phenol:chloroform extraction and used for ChIP-qPCR and subsequently processed for next generation sequencing as follows:
Next generation sequencing
The Biopolymers Facility (Harvard Medical School, Boston, MA, USA) conducted quality control testing on an Angilent BioAnalyzer
followed by Wafergen PrepX DNA ChIP library preparation. Pooled libraries were loaded onto two lanes of HiSeq Rapid v2 flow cell
(Illumina) with PhiX control adaptor-ligated library (Illumina) spiked-in at 5% by weight to ensure balanced diversity and to monitor
clustering and sequencing performance. Single-end 50 bp reads were generated on a HiSeq 2500 Sequencing System.
RNA-seq
Stable T47D cells were hormone deprived for 5 days in charcoal-stripped containing media then grown for another 48h in the
absence or presence of 10 nM E2. RNA was isolated using RNeasy Mini Kit (QIAGEN) according to manufacturer’s directions and
subjected to on column DNase (QIAGEN) digestion to remove genomic DNA before final elution in water. The Genomic and RNA
Profiling Core (Baylor College of Medicine, Houston, TX, USA) conducted sample quality checks using the NanoDrop spectrophotometer and Agilent Bioanalyzer 2100 followed by subsequent Illumina TruSeq Stranded mRNA library preparation protocol
(p/n 15031047, rev. E) as follows: A double-stranded DNA library was created using 180ng of total RNA (measured by picogreen),
with the Illumina TruSeq Stranded mRNA-Seq Sample Prep kit (cat# RS-122-2101). First, cDNA was created using the fragmented
30 poly(A) selected portion of total RNA and random primers. During second strand synthesis, dTTP is replaced with dUTP which
quenches the second strand during amplification, thereby achieving strand specificity. Libraries were created from the cDNA by first
blunt ending the fragments, attaching an adenosine to the 30 end and finally ligating unique adapters to the ends. The ligated products
were then amplified using 15 cycles of PCR. The resulting libraries were quantified using a NanoDrop spectrophotometer and fragment size assessed on an Agilent Bioanalyzer. A qPCR quantification was performed on the libraries to determine the concentration
of adaptor ligated fragments using Applied Biosystems ViiA7 Real-Time PCR System and a KAPA Library Quant Kit (cat# KK4824).
Using the concentration from the ViiA7 qPCR machine above, 27 pM of library was loaded onto two lanes of a high output v4 flowcell (Illumina p/n PE-401-4001) and amplified by bridge amplification using the Illumina cBot machine (cBot protocol: PE_HiSeq_
Cluster_Kit_v4_cBot_recipe_v9.0). PhiX Control v3 adaptor-ligated library (Illumina p/n 15017666) is spiked-in at 2% by weight to
ensure balanced diversity and to monitor clustering and sequencing performance. Paired-end 100 bp reads were generated on a
HiSeq 2500 Sequencing System (Illumina p/n FC-401-4003).
Quantitative PCR
qPCR was performed using SsoAdvanced SYBR green Supermix (Bio-Rad) and 0.5 mM primers (Sigma) listed in Key Resources
Table and run on a LightCycler 96 (Roche). All samples were run in triplicate and values shown are the average ± SEM of at least
2 independent experiments. For ChIP-qPCR, 1% inputs were run for each corresponding sample and primers against a region on
Chr20 which ERa does not bind was used as a negative control. Chromatin captured from HA-ChIP in YFP-HA cells were used
as control instead of IgG antibody alone. For mRNA-qPCR (Figures 3D, S3F, 4C, and S4B), RNA was extracted as described above
from stable T47D cells grown in hormone deprived media for 5 days, before growing another 24h in the absence (–E2) or presence of
10 nM E2 and/or 1 mM fulvestrant as indicated. One step quantitative RT-PCR was performed using iScript reverse transcriptase
(Bio-Rad) with 25 ng RNA. Expression was normalized to GAPDH and relative expression was calculated as fold change using
the 2–DDCt method with YFP –E2 set to 1.
Immunohistochemistry
IHC staining was performed with assistance from The Lester and Sue Smith Breast Center Pathology Core at Baylor College of Medicine (Houston, TX, USA). Tissue sections were incubated at 58 C overnight in a dry slide incubator and deparaffinized in xylene and
graded alcohol washes. Antigen retrieval was performed in 0.1 M Tris-HCl pH 9.0 following by quenching in 3% H2O2. The following
antibodies were used to stain for 1h at RT: ERa (clone 6F11, Novocastra, 1:200), pRb (Ser780) (clone D59B7, Cell Signaling, 1:25),
Ki67 (clone MIB-1, Dako, 1:200), and PR (clone PgR 1294, Dako, 1:1600). After washing in TBS, EnVision labeled polymer-HRP antimouse or anti-rabbit antibodies (Dako) were added for 30 min. at RT. Slides were washed with TBS then developed with DAB+ solution (Dako) and DAB sparkle enhancer (Biocare). After washing in TBS, slides were counstained with Hematoxylin, dehydrated, and
cleared before coverslipping with Cytoseal (VWR). ER positive staining cells were quantified in lung sections from 5 T47D xenograft
bearing mice. Stained WHIM18 tumor and lung sections were quantified from 5 mice per treatment group.
Scratch Wound Assay
Stable T47D cells were hormone deprived for 7 days before seeding in hormone deprived media at 50,000 cell/well in a 96-well
ImageLock plate (Essen BioScience). The following day, cells were treated 10 mg/mL mitomycin C (Sigma) for 2h before wounding
with a WoundMaker (Essen BioScience). Cells were washed with hormone deprived media then fresh hormone deprived media containing mitomycin C was added. Images were acquired every 3h for 72h with an IncuCyte live-cell analysis system (Essen
BioScience). Fresh hormone deprived media plus mitomycin C was changed every 24h. Cell motility assessed by the relative wound
density (RWD) calculated by measuring density in the wound area relative to the density outside the wound area at 72h. The RWD is
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0% at 0h and 100% when the density inside the wound is the same as the density outside the wound, therefore normalizing for
changes in density due to proliferation outside the wound. Representative images are depicted and quantification from average
of three independent experiments ± SEM are shown. P-values based on ANOVA followed by Dunnett’s post hoc test for multiple
comparisons correction.
Immunofluorescence Microscopy
Hormone deprived stable T47D cells were seeded onto poly-D-lysine coated coverslips (Fisher) and grown overnight. Cells were
fixed with 4% formaldehyde for 20 min. at RT followed by permeabilization with 0.2% Triton X-100 for 10 min at RT and blocking
with 10% normal goat serum for 1h. Antibodies against E-cadherin (cat# 14472, Cell Signaling, 1:50), vimentin (cat# 5741, Cell
Signaling, 1:100) or HA-tag (cat# 2367, Cell Signaling, 1:50) were incubated overnight at 4 C then goat anti-mouse-488 (cat#
A-11011, Invitrogen, 1:1000), goat anti-rabbit-488 (cat# A-11008, Invitrogen, 1:1000), or goat anti-mouse-568 (cat# A-11004, Invitrogen, 1:1000) was added for 30 min at RT. Coverslips were mounted onto slides with ProLong Gold Antifade Reagent (Invitrogen).
Fluorescence images were acquired on a Nikon Eclipse Ti microscope equipped with a CoolSNAP EZ camera (Photometrics Scientific) using a Plan Apo 40X/0.95 aperture objective and Nikon NIS elements software. Images were quantified with ImageJ by setting a
threshold from E-cadherin fluorescence channel from ESR1-WT cells which gave cell surface appearance. The same threshold was
applied to images acquired from all other cell lines and cells were considered E-cadherin+ when cell surface signal was present using
the described threshold. 2-3 images per cell line were quantified and shown are averages from two independent experiments ± SEM.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical tests were performed with GraphPad Prism 7. P-values less than 0.05 were considered statistically significant (*p < 0.05,
** p < 0.01, *** p < 0.001, **** p < 0.0001). For box and whiskers plots, the box depicts interquartile range with median line and whiskers
extending to minimum and maximum values for each group.
Immunofluorescence images were quantified with ImageJ by setting a threshold from E-cadherin fluorescence channel from
ESR1-WT cells which gave cell surface appearance. The same threshold was applied to images acquired from all other cell lines
and cells were considered E-cadherin+ when cell surface signal was present using the described threshold. 2-3 images per cell
line were quantified and shown are averages from two independent experiments ± SEM.
For cell proliferation assays, significance was determined based on one-way ANOVA followed by Tukey’s post hoc test for multiple
comparisons correction for ESR1-e6>YAP1 or ESR1-e6>PCDH11X fusion-expressing cells compared to all other stable T47D cells
within a treatment group (indicated by asterisks) or using two-way ANOVA followed by Bonferonni’s post hoc test for multiple comparisons correction for each construct after E2 stimulation, +E2 versus –E2 (#### p < 0.0001). Data are mean ± SEM of three independent experiments. For palbociclib sensitivity assays in stable T47D and MCF7 cell lines, each point represents averages ± SEM
from 3-4 independent experiments of relative cell growth for indicated palbociclib dose, calculated by taking the palbociclib treated
Day 12/Day 1 alamarBlue reading ratio divided by vehicle treated Day 12/Day 1 ratio. P-values describes significance between
YFP +E2, ESR1-e6>YAP1, and ESR1-e6>PCDH11x slopes compared to YFP –E2 as measured by ANOVA with Tukey’s post hoc
analysis for multiple comparisons.
For ChIP-qPCR assays, bar graphs depict enrichment of ER binding regions in hormone deprived stable T47D cells before and
after stimulation with E2 (100 nM) for 45 min as determined by HA-ChIP followed by qPCR for ER binding regions of estrogen responsive genes as indicated and negative ER binding region. Average values from 3 experiments are shown ± SEM. Asterisks denote significant differences in binding compared to WT-ER –E2 for each gene binding region as determined by ANOVA followed by Tukey’s
post hoc test.
In Vivo Analysis
For T47D xenograft assays, significance of tumor volumes Day 146 post injection was determined based on Kruskal-Wallis test followed by Dunn’s post hoc analysis for multiple comparisons correction comparing YFP –E2 to all other groups with N = 6 mice per
group. For ER+ cell counting in the lungs, ER+ cells from IHC images of 5 mice bearing xenografted tumors at Day 146 were manually
counted. Statistical analysis was based on Kruskal-Wallis test with Dunn’s post hoc analysis for multiple comparisons correction
comparing YFP versus fusion-bearing groups and YFP +E2.
For WHIM18 PDX assays, Figure 5B depicts averages of tumor volumes from 8-11 mice per group ± SEM are shown. P-value
determined by unpaired t test describes significance of tumor growth rates (slopes) derived from tumor volumes at day of randomization/start of treatment (Day 61 post transplantation) to experiment end (Day 91 post transplantation) for vehicle and palbociclib
treated mice. Figure S5C depicts tumor growth rates as described above for all tumors measured in each condition. Middle line represents mean tumor volume ± SD. Day 0 post treatment is the same as treatment start/Day 61 post transplantation and represents
the tumor growth rate from time tumors were palpable (Day 49 post transplantation) up to treatment start date. Day 30 is the same as
Day 91 post transplantation and represents on-treatment tumor growth rates. P-values determined by one-way ANOVA with Tukey’s
post hoc analysis for multiple comparisons. For IHC images, positive staining cells were quantified in tumor and lung sections from
5 mice per treatment group. Bar graphs represents mean ± SD and P-values indicate significance as determined by Wilcoxon
rank-sum tests.
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ChIP-seq Analysis
Single-end 50 bp reads were aligned to hg19 (GRCh37) reference genome using BWA (Li and Durbin, 2010) and alignment files were
converted to BED format using BEDTools (Quinlan and Hall, 2010). BED files were used for peak calling by MACS v1.4.2 (Zhang et al.,
2008). MACS peaks (p < 1e–7 cutoff and associated FDRs) were annotated with GREAT (McLean et al., 2010) using default settings.
Motif analysis was performed by taking 100 bp sequences centered on the summit of peaks and submitted for enrichment analysis
using MEME-ChIP in normal mode (Bailey and Elkan, 1994). P-values represents the probability that an equal or better site would be
found in a random sequence of the same length conforming to the background letter frequencies (Bailey and Elkan, 1994).
RNA-seq Analysis
Paired-end 100 bp reads were aligned to hg19 (GRCh37) reference genome using RSEM v1.2.31 (Li and Dewey, 2011) and Bowtie 2
(Langmead and Salzberg, 2012). TPM (Transcripts Per Million) values calculated by RSEM were log2 transformed and row Z-scores
were generated for the all heatmaps shown. Differential gene expression analysis was performed using EBseq (Leng et al., 2013) with
FDR < 0.1 as a cutoff comparing 4 groups: (1) YFP +E2 versus YFP –E2, (2) ESR1-e6>YAP1 –E2 versus YFP –E2, (3) ESR1e6>PCDH11X –E2 versus YFP –E2, and (4) ESR1-e6>NOP2 –E2 versus YFP –E2. Hierarchal clustering was performed on differentially expressed genes for which a nearby binding site within 1 Mb was observed by ChIP-seq shared by ESR1-WT, ESR1-e6>YAP1,
ESR1-e6>PCDH11X, and ESR1-e6>NOP2 for Figure 3C. Clustering was also performed on differentially expressed genes for which a
nearby site within 1 Mb was selectively bound by both ESR1-e6>YAP1 and ESR1-e6>PCDH11X but bound by ESR1-WT nor ESR1e6>NOP2 (Figure S4C).
DATA SOFTWARE AND AVAILABILITY
The accession number for the ChIP and RNA sequencing data from T47D reported in this paper is GEO: GSE116170. TCGA data for
fusion gene discovery and for gene expression analysis can be downloaded from https://portal.gdc.cancer.gov/ and https://portal.
gdc.cancer.gov/legacy-archive. RNA-seq of human primary breast tumors from two neoadjuvant aromatase inhibitor clinical trials
can accessed through dbGaP phs000472.

Cell Reports 24, 1434–1444.e1–e7, August 7, 2018 e7

Cell Reports, Volume 24

Supplemental Information

Functional Annotation of ESR1 Gene Fusions
in Estrogen Receptor-Positive Breast Cancer
Jonathan T. Lei, Jieya Shao, Jin Zhang, Michael Iglesia, Doug W. Chan, Jin Cao, Meenakshi
Anurag, Purba Singh, Xiaping He, Yoshimasa Kosaka, Ryoichi Matsunuma, Robert
Crowder, Jeremy Hoog, Chanpheng Phommaly, Rodrigo Goncalves, Susana
Ramalho, Raquel Mary Rodrigues Peres, Nindo Punturi, Cheryl Schmidt, Alex
Bartram, Eric Jou, Vaishnavi Devarakonda, Kimberly R. Holloway, W. Victoria Lai, Oliver
Hampton, Anna Rogers, Ethan Tobias, Poojan A. Parikh, Sherri R. Davies, Shunqiang
Li, Cynthia X. Ma, Vera J. Suman, Kelly K. Hunt, Mark A. Watson, Katherine A.
Hoadley, E. Aubrey Thompson, Xi Chen, Shyam M. Kavuri, Chad J.
Creighton, Christopher A. Maher, Charles M. Perou, Svasti Haricharan, and Matthew J.
Ellis

ESR1-e6>NOP2

ESR1

NOP2

ESR1-e6>AKR1D1
ESR1
AKR1D1

ESR1-e6>PCDH11X
ESR1
PCDH11X

ESR1-e5>CCDC170 (TCGA-D8-A27N)
ESR1
CCDC170

ESR1-e7>POLH (TCGA-BH-A1FD)
POLH
ESR1

ESR1-e3>CCDC170 (TCGA-AR-A24R)
ESR1
CCDC170

ESR1-e6>AKAP12 (TCGA-BH-A1FD)
ESR1
AKAP12

ESR1-e6>YAP1

ESR1

YAP1

Figure S1 related to Figure 1. PCR validation of ESR1 fusions. cDNAs were synthesized from patient RNA or WHIM18 tumor RNA,
followed by PCR amplification and sanger sequencing. Black line indicates fusion break point. Sequences contributed by ESR1 are to the left
of the breakpoint and from fusion partner sequences to the right of the breakpoint.

P2
ES

R

1-

W

e6

T

O
ES

R

1-

1e

6>
-N

>P
C

e6
1R

ES

+

ES

kDa
90
80

11
X

H

D

1

>Y
AP
e6
Fulv: −

R

1-

ESR1
fragments

YF
P

Relative Growth

Out-of-frame
ESR1 fusions

T47D

R

B

T47D

ES

A

−

−

−

−

−

+
*

70

*

+
*

*

+
*

60

+

+

*

ERα

50

*

40

*

β-Actin

40

5

*

**

***

70

P2

H

–E2, +Fulvestrant

+E2

ESR1-e6

ESR1-WT

ESR1-e6>NOP2

ESR1-e6>YAP1

ESR1-e6>PCDH11X

YFP

ESR1-WT

ESR1-e6

ESR1-e6>NOP2

ESR1-e6>PCDH11X

YFP

ESR1-e6>YAP1

ESR1-WT

ESR1-e6

ESR1-e6>NOP2

ESR1-e6>PCDH11X

ESR1-e6>YAP1

YFP

ESR1-e6

ESR1-WT

ESR1-e6>NOP2

ESR1-e6>YAP1

ESR1-e6>PCDH11X

YFP

–E2

T
W
R

ES

R
ES

−

−

−

−

−

−

+

+
*

*

+
*

*

+
*

+

*

+

ERα

60

0

1-

e6
1-

e6
R

ES

R

1-

e6

>P

C

O

D

1
kDa
90
80

ES

Fulv:

1-

e6
1****

####

R

****

ES

P

****

10

####

YF

Relative Growth

####
####

####

11
X

MCF7

>N

D

MCF7

15

>Y
AP

C

50
40

40

*

*

β-Actin

+E2, +Fulvestrant

Figure S2 related to Figure 2. Out-of-frame ESR1 fusions lack estrogen-independent growth promoting ability and in-frame ESR1 fusions from endocrine refractory disease
promotes estrogen-independent and fulvestrant-resistant growth. (A) Bar graphs depicting growth of hormone deprived stable out-of-frame ESR1 fusion or ESR1 fragments expressing
T47D cells in the absence (open bars) or presence of fulvestrant (black bars). Data are average of 3 independent experiments ±SEM. (B) Western blotting of ERα in hormone deprived
stable T47D cells treated in the absence of presence of fulvestrant. Asterisks denote ESR1 fusion or ESR1-e6. β-Actin used as loading control. (C) Similar to Figure 2C, except hormone
deprived stable MCF7 cells expressing the indicated constructs were used. Significance was determined based on ANOVA followed by Tukey’s post-hoc test for multiple comparisons
correction for ESR1-e6>YAP1 or ESR1-e6>PCDH11X fusion expressing cells compared to all other stable T47D cells within a treatment group (**** p < 0.0001, ** p < 0.01, * p < 0.05)
or using two-way ANOVA followed by Bonferonni’s post-hoc test for multiple comparisons correction for each construct after E2 stimulation, –E2 vs +E2 (#### p < 0.0001). Data are
mean ± SEM of three independent experiments. (D) Similar to (B) except hormone deprived stable MCF7 cells were used.

A

Anti-HA

B

DAPI

WT-HA
ESR1-e6>YAP1-HA

150
100
60
50
40
30
20
10
0

ES
R
1e6
ES
R
1ES
W
R
T
1
-e
ES
6
R
>Y
1A
e6
P1
>P
C
D
ES
H
11
R
X
1e6
>N
O
P2
ES
R
1Y5
37
S

ESR1-e6>NOP2-HA

Ve
ct
or

ESR1-e6>PCDH11X-HA

–E2
+E2

C

ESR1-E6-HA

T47D

HEK293T

200

Fold Change in Luciferase Activity

Merge

Parental

ERα

A
A

ER-fusions
ER-WT

0
150

50

0

6

PGR

4

2

0

A

A

-H

-H
O

P2

11
X

>N
e6
1R

Figure S3 related to Figure 3. In-frame ESR1 fusions bind EREs but have differential abilities to
drive transcription. (A) Immunofluorescence staining with Anti-HA antibody, pseudocolored in red,
was performed on hormone-deprived stable T47D cells as indicated, showing nuclear localization of all
HA-tagged ESR1-WT, ESR1 fusions, and ESR1-e6 truncation. Parental T47D cells lacking exogenous
expression of any construct was used as a negative control. DAPI stained nuclei pseudocolored in blue.
10 µm scale bar. (B) Bar graphs depicting ERE-luciferase reporter activity in hormone-deprived HEK293T cells ±2.5 nM E2 for 24h. Averages of Firefly/Renilla luminescence readings from each sample
were calculated and expressed as fold change in activity relative to Vector transfected –E2. Shown are
the averages of two independent experiments ±SEM. (C) Full-length ESR1(wt) or ESR1 fusions were
transfected into HEK293T cells and subjected to pulldown with 3X ERE(wt) or ERE(mut) containing a
DNA binding inactivating double zinc finger mutations as negative controls and analyzed by western
blotting using a N-terminal ER antibody along with 10% input as positive controls. (D) Lysates from
hormone deprived stable T47D cells stimulated with E2 (15 min) were immunoprecipitated with an HA
antibody or rabbit IgG control then blotted with N-terminal ERα antibody demonstrating successful IP of
fusion ER (asterisks) and WT-ER (top panel). Blotting with a C-terminal ERα antibody that recognizes
only WT-ER detects strong co-IP with WT-ER but lack of WT-ER co-IP with ER fusions. (E) Whole cell
lysates (inputs) analyzed by Western blot from (C) with N- and C-terminal ER antibodies along with βActin control. (F) Same as Figure 3D, except –E2 and +E2 conditions shown for all cell lines analyzed.

50

H

β-Actin

ES

50

100

A

ER-WT

TFF1

D

70
60

IB: Anti-ER (C-term)

-H

100
90
80

C

*

P1

*

>P

*

e6

*

5

YA

W
1R
IB: Anti-ER (N-term)

1-

A

P2

TH

O
>N
e6

1R
ES

+

Relative mRNA

-H

11
x
D
C

>P
e6

ES

R

1-

e6
ES
*

−

R

ER-WT

*

+

ES

IB: Anti-ER (C-term)

70
60

−

+

+E2, +Fulv

A

ER-fusions
ER-WT
IgGH

−

+

–E2, +Fulv

10

H

*

−

+E2

P-

*

+

GREB1

1e6
>

*

100
90
80

R

H
PYF
E2: −

IgG

IB: Anti-ER (N-term)
*

1-

A

W
1R
ES
+

H

H
1>Y
AP

A
TH

O
>N
e6

1R
ES

A

A
-H
P2

H
D
C
>P

e6
R

ES

R
ES
*

−

–E2

R

50

*

+

15

T47D

YF

70
60

−

+

Relative mRNA

100
90
80

−

+

Relative mRNA

50

−

-H

A
-H
11
x

A
H
1>Y
AP
70
60

+

1-

e6
1-

A
H
PYF
E2: −
100
90
80

F

T47D

Whole Cell Lysates

ES

E

T47D

IP: Anti-HA

ES

D

ESR1-WT-HA

DAPI
E-cadherin

ESR1-e6>YAP1-HA

ESR1-e6>PCDH11X-HA

A

A

-H

-H
C

D

6>
-N

H

O

P2

11
X

-H
P1
>Y
A

1e

>P

ES

R

e6
1R
ES

p < 0.0001

40

ns

20

A
-H
O

>N

H
D

e6

C
ES

R

1-

>P
e6

1-

P2

11
X

P1
>Y
A

ES

1.67E-06 8.34E-05

-H

A
-H

H
P-

p-value FDR

A

0

e6

Pathway
UV Response Down

p < 0.0001

A

GSEA analysis for differentially expressed genes
selectively bound by
ESR1-e6>YAP1 and ESR1-e6>PCDH11X

T47D Motility

60

YF

ISM1
GJA1
KCNJ2
TGFBR3
KIF13A
IRS1
MANEAL
PADI3

ESR1-WT-HA, –E2
(999 sites)

0

A

A
H
Pe6
1-

D

Epithelial Mesenchymal Transition 5.19E-04 1.30E-02

2

MDA-MB-231
ESR1-e6>NOP2-HA

–

F

G

100
80
60
40

MCF7, –E2
YFP

Fulv: –
siESR1: –

–
+

+
–

ESR1-e6>YAP1
+
+

–
–

–
+

+
–

+
+

90
80

ER-YAP1

70
60
40

ER
Snail

20

ES ES E
R R1 SR
1- - 1
e e ES 6>P 6>Y WT
R CD AP -HA
1- H 1
e6 1 -H
> 1 A
M NO X-H
D P A
A 2-M H
B A
-2
31

0

DAPI
Vimentin

Relative mRNA

YF
R

– – + + – +

T47D

ESR1:

5
0

T
A

16

15

14

13

12

11

9

10

8

7

E2: – – + +

64

-2

E

10

1-

448

T

15

R

ESR1-e6>NOP2-HA, –E2
(48 sites)

G

VCAN

20

ES

ESR1-e6>YAP1-HA, –E2
(459 sites)
2
1

48

AT

C

+E2, +Fulv
5

Relative Wound Density (%)

445

AT

G
C

% Cell Surface
E-cadherin+ cells

ESR1-e6>PCDH11X-HA, –E2
(1987 sites)

1028

T

GTG
T

CC

G
A
A

7.5e-21

+E2

Differentially expressed genes selectively bound by
ESR1-e6>YAP1 and ESR1-e6>PCDH11X

Binding sites identified by ChIP-seq:

71

GC

–E2, +Fulv

R

C

A

G

AC

ERE

–E2

10

0
25

P-Value

SNAI1

ES

2

5

AT

T
6

C

GG

4

0

TCA
3

1

2

bits

2

Name

15

Relative mRNA

GG C T
Sequence Logo

YFP-HA
ESR1-e6>NOP2-HA
YFP-HA
ESR1-e6>NOP2-HA
ESR1-e6-HA
ESR1-e6-HA

0

COL3A1
GRB14
INHBA
MAML3
ADCY1
NRIP1
VCAN
SULF1
GFRA1
KCNK15
TGM2
RIMS4
SERPINA1
FAM134B
LOXL4
SNAI1
SPINK13

ESR1-e6>YAP1-HA
ESR1-e6>PCDH11X-HA
ESR1-e6>YAP1-HA
ESR1-e6>PCDH11X-HA

-2

+ + +

1

– – + +

B

Motif enrichment analysis of binding sites for genes up-regulated by
ESR1-YAP1 and ESR1-PCDH11X vs ESR1-WT and ESR1-NOP2:

YFP-HA
ESR1-e6>NOP2-HA
ESR1-e6-HA

E2: – – –

ESR1-e6>YAP1-HA
ESR1-e6>PCDH11X-HA
ESR1-e6>YAP1-HA
ESR1-e6>PCDH11X-HA

YFP-HA
ESR1-e6>NOP2-HA
ESR1-e6-HA

A

30

E-Cadherin

120
100
50

β-Actin

40

1

2

3

4

5

6

7

8

Figure S4 related to Figure 4. Active ESR1 fusions promote metastasis by up-regulating an EMT-like transcriptional program. (A)
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Same as in Figure 4F, except using stable MCF7 cell lines.
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Table S1. Related to Figure 1 and Table S2. Summary of ESR1 fusion transcripts from ER+ samples. The TCGA dataset includes 728 breast cancer patients (Ciriello et al., 2015). The
NeoAI Trials dataset includes 41 aromatase inhibitor sensitive neoadjuvant primary samples, 40 aromatase inhibitor resistant neoadjuvant primary samples (Ellis et al., 2011; Olson et al.,
2009). The Late Stage dataset includes 25 advanced ER+ endocrine therapy refractory, metastatic biopsy samples (Table S2) and includes WHIM18, a PDX derived from a metastatic
biopsy from a patient with endocrine therapy resistant disease (Li et al., 2013). ChimeraScan (Iyer et al., 2011) and INTEGRATE (Zhang et al., 2016) were used to detect gene fusions in
RNA-seq data and in some cases with whole genome data. ESR1 fusions are presented according to the number of 5’ exons (top portion of table) or 3’ exons (bottom portion of table)
retained in each of the indicated ESR1 fusions with corresponding amino acids (aa). The first two 5’ exons of ESR1 (e2) are non-coding exons. The -> indicates direction of fusion
transcript from 5’ to 3’ direction. Also shown are mutational status of genes found to be significantly mutated in ER+ breast cancer representing common risk factors for hormone receptor
positive breast cancer (Ellis et al., 2012) and platform used to determine mutational status (WES, whole-exome sequencing; WGS, whole-genome sequencing).

Oligonucleotides
mRNA-qPCR primers:
GREB1: Forward, 5’CAAAGAATAACCTGTTGGCCCTGC-3’
GREB1: Reverse, 5’GACATGCCTGCGCTCTCATACTTA-3’
TFF1: Forward, 5’-GTGTCACGCCCTCCCAGT-3’
TFF1: Reverse, 5’-GGACCCCACGAACGGTG-3’
PGR: Forward, 5’-CTTAATCAACTAGGCGAGAG-3’
PGR: Reverse, 5’-AAGCTCATCCAAGAATACTG-3’
SNAI1: Forward, 5’-TCGGAAGCCTAACTACAGCGA-3’
SNAI1: Reverse, 5’-AGATGAGCATTGGCAGCGAG-3’
VCAN: Forward, 5’CCAGTGTGAACTTGATTTTG-3’
VCAN: Reverse, 5’CAACATAACTTGGAAGGCAG-3’
GAPDH: Forward, 5’CTTTTGCGTCGCCAG-3’
GAPDH: Reverse, 5’TTGATGGCAACAATATCCAC-3’
ChIP-qPCR primers:
GREB1 ERE: Forward, 5’AGCAGTGAAAAAAAGTGTGGCAACTGGG-3’
GREB1 ERE: Reverse, 5’CGACCCACAGAAATGAAAAGGCAGCAAACT-3’
TFF1 ERE3: Forward, 5’GTCGTTGCCAGCGTTTCC-3’
TFF1 ERE3: Reverse, 3’CTTCTCCACGCCCTGTAAATTT-3’
PGR Enhancer: Forward, 5’GATGACAGAAGGAGAAGTTAGAAG-3’
PGR Enhancer: Reverse, 5’ATATGGCATTGAAGCAACAGG-3’
Chr20 negative region: Forward, 5’GAGGCTGTGCTTGGAGTAGG-3’
Chr20 negative region: Reverse, 3’CGTTTCCCCTGTGAAAGGTA-3’
siESR1: Sense, 5’GAAAGAUUGGCCAGUACCA-3’
siESR1: Antisense, 5’UGGUACUGGCCAAUCUUUC-3’

Reference:
This paper

Identifier:
N/A

This paper

N/A

This paper

N/A

This paper

N/A

Sigma-Aldrich

FH1_VCAN

Sigma-Aldrich

RH1_VCAN

Sigma-Aldrich

FH2_GAPDH

Sigma-Aldrich

RH2_GAPDH

Lin et al., 2004

N/A

This paper

N/A

This paper

N/A

Carroll et al., 2006

N/A

Sigma-Aldrich

Oligo#3020649250000030
Oligo#3020649250000040

Sigma-Aldrich

Table S4. Sequences of mRNA-qPCR and ChIP-qPCR primers, and siRNA. Related to STAR Methods.

